Constipation Laxative Market Report 2026

The constipation laxative market size has grown strongly in recent years. It will grow from $7.42 billion in 2025 to $7.86 billion in 2026 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to widespread prevalence of constipation disorders, long-standing use of stimulant and osmotic laxatives, availability of affordable over-the-counter treatments, increasing urban sedentary lifestyles, established presence of hospital and retail pharmacy distribution.

The constipation laxative market size is expected to see strong growth in the next few years. It will grow to $9.8 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to aging global population, rising incidence of chronic digestive disorders, increasing awareness of gut health, growth in self-medication practices, expanding access through online pharmacies. Major trends in the forecast period include growing preference for gentle and long-term constipation management, rising demand for bulk-forming and fiber-based laxatives, increased use of osmotic laxatives for chronic constipation, expansion of over-the-counter laxative availability, rising adoption of oral laxative formulations.

The rising prevalence of constipation is anticipated to drive the growth of the constipation laxative market in the coming years. Constipation is a condition marked by infrequent bowel movements, usually fewer than three per week, along with difficulty passing hard and dry stools. The incidence of constipation has been increasing due to several factors, such as shifts in dietary patterns, sedentary lifestyles, insufficient fluid consumption, and certain medical conditions or medications. Constipation laxatives are used to relieve constipation by stimulating bowel activity or softening stools. They assist in restoring regular bowel movements and reducing discomfort when dietary and lifestyle modifications are not adequate. For example, in January 2024, a survey of 1,139 participants aged 18 and above conducted in Saudi Arabia by Cureus, a US-based peer-reviewed journal, reported that 811 participants, representing 71.2% of the total, experienced either current or past constipation. Hence, the growing prevalence of constipation is contributing to the expansion of the constipation laxative market.

Leading companies operating in the constipation laxative market are emphasizing the development of innovative products, such as ayurvedic liquid laxatives, to meet the demand from consumers seeking effective and palatable constipation remedies. An ayurvedic liquid laxative is a herbal-based formulation intended to relieve constipation by promoting bowel movements, providing a natural alternative among constipation treatments. For instance, in December 2023, Lupin Life, an India-based pharmaceutical company, introduced Softovac Liquifibre, a 100% ayurvedic liquid laxative. This novel product blends Isabgol fiber with natural ingredients such as Sonamukhi, Harad, Mulethi, Saunf, Amaltas, and Gulab Dal. Softovac Liquifibre delivers a mild, non-habit-forming solution for constipation and is enhanced with advanced technologies to achieve optimal particle size and a mango flavor, while also catering to consumer preferences for palatable and diabetic-friendly products.

In January 2023, Nuance Medical, a US-based healthcare company, acquired Beutlich Pharmaceuticals along with its HurriCaine brand for an undisclosed sum. This acquisition strengthens Nuance Medical’s portfolio in the medical products segment, particularly in pain management and anesthesia, and broadens its footprint in the medical products market. Beutlich Pharmaceuticals is a US-based pharmaceutical company that manufactures laxative suppositories for the relief of occasional constipation.

Major companies operating in the constipation laxative market are Procter & Gamble Corporation, Johnson & Johnson Services Inc., Merck & Co. Inc., Bayer AG, Sanofi S.A, AstraZeneca PLC, Abott Laboratories, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmBH, Reckitt Benckiser Group plc, Fresenius Kabi AG, Daiichi Sankya Company Limited, Eisai Co. Ltd, Sun Pharmaceutical Ltd, Shionogi & Co. Ltd, Dr. Reddy's Laboratories Ltd., Cipla Limited, Mallinckrodt Pharmaceuticals, Ironwood Pharmaceuticals, Beutlich Pharmaceuticals LLC.

North America was the largest region in the constipation laxative market in 2025. The regions covered in the constipation laxative market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the constipation laxative market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the constipation laxative market by increasing the cost of imported active pharmaceutical ingredients, excipients, and packaging materials used in oral and rectal formulations. these effects have been most pronounced in osmotic and bulk-forming laxative segments, particularly in north america and europe where api sourcing is globally diversified. asia-pacific markets have experienced pricing pressure due to trade-related supply disruptions. however, tariffs have encouraged domestic api manufacturing and local formulation production, supporting supply chain stability and improved product availability.

The constipation laxative market research report is one of a series of new reports that provides constipation laxative market statistics, including constipation laxative industry global market size, regional shares, competitors with a constipation laxative market share, detailed constipation laxative market segments, market trends and opportunities, and any further data you may need to thrive in the constipation laxative industry. This constipation laxative market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Constipation laxatives are medications or agents used to promote bowel movements or soften stools to provide relief from constipation. They consist of several types, including stool softeners and stimulant laxatives. These therapies act through different mechanisms to facilitate the movement of stool through the intestines.

The primary drug types of constipation laxatives include bulk-forming laxatives, stimulant laxatives, osmotic laxatives, and others. Bulk-forming laxatives function by absorbing fluid in the intestines, resulting in a larger, softer stool that is easier to pass. The routes of administration include oral and rectal. Distribution channels comprise hospital pharmacies, retail pharmacies, online pharmacies, and drug stores.

The constipation laxative market consists of sales of enemas and suppositories. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.